Mayne will regain favour soon enough. a few product approvals like today will help fund managers see through whether eanrings are 1-2% above or below forecast and will focus on the eanrings growth potential of this company
A healthcare stock with a PE of under 11, low debt, diversifed with significant earnings grow, is a steal
worth at least 1.50 -170 imo
Ann: FDA approval and first generic launch of Acticlate tablets, page-22
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.94 |
Change
-0.010(0.25%) |
Mkt cap ! $335.1M | |||
| Open | High | Low | Value | Volume |
| $3.96 | $4.01 | $3.89 | $510.9K | 129.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 564 | $3.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.96 | 138 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |